Product
AAV5-hFIXco-Padua
Aliases
AAV5-hFIXco-Padua (AMT-061)
3 clinical trials
1 indication
Indication
Hemophilia BClinical trial
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia BStatus: , Estimated PCD: 2035-03-01
Clinical trial
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia BStatus: Active (not recruiting), Estimated PCD: 2021-09-22
Clinical trial
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia BStatus: Completed, Estimated PCD: 2018-10-30